
Albireo Pharma ALBO
Albireo Pharma Total Assets | ALBO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 302 M | 286 M | 165 M | 185 M | 73.2 M | 49.7 M | 6.97 M | 25.4 M | 41.2 M | 41.1 M | 41.5 M | 32.6 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 302 M | 6.97 M | 104 M |
Quarterly Total Assets Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 321 M | 229 M | 261 M | 302 M | 296 M | 219 M | 250 M | 286 M | 311 M | 184 M | 182 M | 165 M | 171 M | 182 M | 173 M | 185 M | 194 M | 204 M | 213 M | 73.2 M | 77.1 M | 82.7 M | 40.3 M | 49.7 M | 31.4 M | 34.2 M | 37.9 M | 6.97 M | 45.1 M | 18.8 M | 21 M | 21 M | 25.7 M | 30.3 M | 37 M | 37 M | 44.4 M | 30.3 M | 37.3 M | 37.3 M | 46.9 M | 34 M | 38.1 M | 38.1 M | 45.1 M | 41.5 M | 41.5 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 321 M | 6.97 M | 116 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
uniQure N.V.
QURE
|
825 M | $ 19.32 | -4.5 % | $ 1.11 B | ||
|
Ultragenyx Pharmaceutical
RARE
|
1.53 B | $ 16.46 | -4.41 % | $ 1.62 B | ||
|
Rafael Holdings
RFL
|
83.1 M | $ 0.94 | 5.89 % | $ 48.3 M | ||
|
REGENXBIO
RGNX
|
453 M | $ 7.16 | -0.35 % | $ 369 M | ||
|
Rigel Pharmaceuticals
RIGL
|
514 M | $ 40.05 | -2.78 % | $ 720 M | ||
|
Celsion Corporation
CLSN
|
12.3 M | - | -6.63 % | $ 13.9 M | ||
|
I-Mab
IMAB
|
2.61 B | - | - | $ 866 M | ||
|
Tenax Therapeutics
TENX
|
104 M | $ 1.27 | -8.27 % | $ 49.8 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
25.6 B | $ 514.68 | -1.15 % | $ 132 B | ||
|
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | ||
|
SELLAS Life Sciences Group
SLS
|
78.3 M | $ 13.67 | -8.01 % | $ 1.49 B | ||
|
CureVac N.V.
CVAC
|
803 M | - | - | $ 867 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
99.6 M | - | 0.74 % | $ 768 M | ||
|
Abcam plc
ABCM
|
1.06 B | - | - | $ 4.9 B | ||
|
Rezolute
RZLT
|
113 M | $ 3.92 | -6.69 % | $ 407 M | ||
|
Midatech Pharma plc
MTP
|
18.2 M | - | -18.52 % | $ 27.3 M | ||
|
Tiziana Life Sciences PLC
TLSA
|
11.3 M | $ 0.63 | -7.05 % | $ 67.2 M | ||
|
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M | ||
|
Affimed N.V.
AFMD
|
97.2 M | - | -34.95 % | $ 21.5 M | ||
|
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
40.5 M | - | -1.58 % | $ 28.1 M | ||
|
Celyad Oncology SA
CYAD
|
19.7 M | - | - | $ 12.5 M | ||
|
Seer
SEER
|
296 M | $ 1.34 | -3.25 % | $ 74.5 M | ||
|
Gracell Biotechnologies
GRCL
|
1.66 B | - | - | $ 3.37 B | ||
|
Summit Therapeutics
SMMT
|
751 M | $ 9.94 | -6.01 % | $ 7.43 B | ||
|
Shattuck Labs
STTK
|
91 M | $ 4.49 | -1.43 % | $ 312 M | ||
|
Silence Therapeutics plc
SLN
|
86 M | $ 19.81 | 0.08 % | $ 2.81 B | ||
|
Soligenix
SNGX
|
9.24 M | $ 0.22 | -8.25 % | $ 1.14 M | ||
|
Sanofi
SNY
|
127 B | $ 46.51 | 0.97 % | $ 56.8 B | ||
|
Spruce Biosciences
SPRB
|
53 M | $ 38.02 | -6.11 % | $ 29.1 M | ||
|
Spero Therapeutics
SPRO
|
68.9 M | $ 0.74 | -10.95 % | $ 41.5 M | ||
|
Sarepta Therapeutics
SRPT
|
3.35 B | $ 13.34 | -5.86 % | $ 1.34 B | ||
|
Savara
SVRA
|
253 M | $ 4.28 | -17.95 % | $ 952 M | ||
|
Teligent, Inc.
TLGT
|
87.8 M | - | -13.85 % | $ 16.1 M | ||
|
Viela Bio, Inc.
VIE
|
423 M | - | - | $ 2.91 B | ||
|
Sutro Biopharma
STRO
|
174 M | $ 8.6 | -1.38 % | $ 73.1 M | ||
|
Tarsus Pharmaceuticals
TARS
|
562 M | $ 72.94 | -6.09 % | $ 3.05 B | ||
|
Supernus Pharmaceuticals
SUPN
|
1.45 B | $ 36.28 | 1.88 % | $ 2.05 B | ||
|
TG Therapeutics
TGTX
|
1.06 B | $ 63.39 | -2.3 % | $ 9.15 B | ||
|
Aphria Inc.
APHA
|
2.5 B | - | -0.45 % | $ 4.87 B | ||
|
Viridian Therapeutics
VRDN
|
899 M | $ 29.91 | -4.87 % | $ 3.05 B | ||
|
Trevi Therapeutics
TRVI
|
193 M | $ 13.35 | -2.73 % | $ 1.8 B | ||
|
Aerpio Pharmaceuticals, Inc.
ARPO
|
44.9 M | - | -0.90 % | $ 104 M | ||
|
Chiasma, Inc.
CHMA
|
176 M | - | -6.00 % | $ 238 M | ||
|
vTv Therapeutics
VTVT
|
89.9 M | $ 16.0 | -2.2 % | $ 64.2 M | ||
|
Adamas Pharmaceuticals, Inc.
ADMS
|
120 M | - | - | $ 376 M | ||
|
Cellect Biotechnology Ltd.
APOP
|
21.3 M | - | 0.38 % | $ 12.9 M | ||
|
Xenon Pharmaceuticals
XENE
|
633 M | $ 36.89 | -1.78 % | $ 2.92 B |